Physician profile
Thor Goodfellow
NPI 1376005850
$2,435.65
in general payments reported to CMS, 2019-2025
30 companies · $935 in 2025
The $935 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.12 · 2021: $94.54 · 2023: $607 · 2024: $786 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.14 |
| Education | $136.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $177.33 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $167.00 | 2019-2025 | |
| Abbott Laboratories | $155.75 | 2024-2025 | Ensite, Merlin@Home |
| Merck Sharp & Dohme LLC | $155.49 | 2024-2025 | Verquvo, Winrevair |
| Janssen Pharmaceuticals, INC | $137.59 | 2023-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $130.77 | 2023-2025 | Camzyos |
| Abiomed | $124.97 | 2023 | Impella |
| Boston Scientific Corporation | $123.54 | 2023-2025 | Latitude Communicator Power Supply |
| Heartflow, INC. | $120.77 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $117.48 | 2025 | Evkeeza |
| Procyrion, INC. | $98.70 | 2024-2025 | Aortix System |
| Astrazeneca Pharmaceuticals LP | $97.68 | 2024-2025 | Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.28 | 2023-2025 | Jardiance |
| Coherus Oncology, INC. | $94.54 | 2021 | |
| Amgen INC. | $90.53 | 2023 | Repatha |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $87.39 | 2024-2025 | Inspire |
| United Therapeutics Corporation | $80.70 | 2024-2025 | Tyvaso, Tyvaso |
| Alnylam Pharmaceuticals INC. | $74.59 | 2025 | Amvuttra |
| Bridgebio Pharma, INC. | $61.31 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $32.79 | 2023 | Uptravi |
| Novo Nordisk INC | $30.88 | 2025 | Wegovy |
| Chiesi USA, INC. | $30.02 | 2023-2024 | Cleviprex, Kengreal, Juxtapid |
| Livanova USA, INC. | $24.86 | 2023 | Tandemlife |
| Irhythm Technologies, INC. | $19.73 | 2024 | Zio Xt Patch, Zio Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $19.04 | 2025 | |
| Ge Healthcare | $18.94 | 2025 | |
| Medtronic, INC. | $18.09 | 2023 | Cobalt Dr Mri Surescan |
| Scpharmaceuticals INC. | $16.96 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $16.68 | 2024 | Arcalyst |
| Merge Healthcare Incorporated | $14.25 | 2023 | Software |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thor Goodfellow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.